Skip to main content
Top
Published in: European Journal of Nuclear Medicine and Molecular Imaging 5/2004

01-05-2004 | Original Article

Risk of second primary cancer following differentiated thyroid cancer

Authors: Emmanuelle Berthe, Michel Henry-Amar, Jean-Jacques Michels, Jean-Pierre Rame, Pascaline Berthet, Emmanuel Babin, Philippe Icard, Guy Samama, Françoise Galateau-Sallé, Jacques Mahoudeau, Stéphane Bardet

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 5/2004

Login to get access

Abstract

Concerns remain over the risk of cancer following differentiated thyroid carcinoma and its causes. Iodine-131 (131I) and external irradiation are known to have potential carcinogenic effects. Thyroid carcinoma is a polygenic disease which may be associated with other malignancies. We investigated the incidence of second cancer and its aetiology in a cohort of 875 patients (146 men, 729 women) with differentiated thyroid carcinoma originating from Basse-Normandie, France. Cancer incidence was compared with that of the general population of the Département du Calvados matched for age, gender and period. The cumulative proportion of second cancer was estimated using the life-table method. Factors that correlated with the risk of second cancer were studied using the Cox model. After a median follow-up of 8 years, 58 second cancers had been observed. Compared with general population incidence rates, there was an overall increased risk of second cancer in women [standardised incidence ratio (SIR)=1.52; P<0.01], but not in men (SIR=1.27; P>0.20). Increased risk related to cancers of the genitourinary tract (SIR=3.31; P<0.001), and particularly to cancer of the kidney (SIR=7.02; P<0.01). Multivariate analysis showed that age above 40 years (P<0.01) and a history of previous primary cancer (P<0.001) correlated with risk. In contrast, neither cervical irradiation nor cumulative activity of 131I was related to the risk. These data confirm that women with differentiated thyroid carcinoma are at risk of developing a second cancer of the genitourinary tract and kidney. Only age and medical history of primary cancer before thyroid carcinoma are risk factors for second cancer. Common environmental or genetic factors as well as long-term carcinogenic effects of primary cancer therapy should be considered.
Literature
1.
go back to reference Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med 1998; 338:297–306.PubMed Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med 1998; 338:297–306.PubMed
2.
go back to reference Hall P, Holm LE, Lundell G, Bjelkengren G, Larsson LG, Lindberg S, Tennvall J, Wicklund H, Boice JD Jr. Cancer risks in thyroid cancer patients. Br J Cancer 1991; 64:159–163.PubMed Hall P, Holm LE, Lundell G, Bjelkengren G, Larsson LG, Lindberg S, Tennvall J, Wicklund H, Boice JD Jr. Cancer risks in thyroid cancer patients. Br J Cancer 1991; 64:159–163.PubMed
3.
go back to reference Dottorini ME, Lomuscio G, Mazzucchelli L, Vignati A, Colombo L. Assessment of female fertility and carcinogenesis after iodine-131 therapy for differentiated thyroid carcinoma. J Nucl Med 1995; 36:21–27.PubMed Dottorini ME, Lomuscio G, Mazzucchelli L, Vignati A, Colombo L. Assessment of female fertility and carcinogenesis after iodine-131 therapy for differentiated thyroid carcinoma. J Nucl Med 1995; 36:21–27.PubMed
4.
go back to reference de Vathaire F, Schlumberger M, Delisle MJ, Francese C, Challeton C, de la Genardiere E, Meunier F, Parmentier C, Hill C, Sancho-Garnier H. Leukaemias and cancers following iodine-131 administration for thyroid cancer. Br J Cancer 1997; 75:734–739.PubMed de Vathaire F, Schlumberger M, Delisle MJ, Francese C, Challeton C, de la Genardiere E, Meunier F, Parmentier C, Hill C, Sancho-Garnier H. Leukaemias and cancers following iodine-131 administration for thyroid cancer. Br J Cancer 1997; 75:734–739.PubMed
5.
go back to reference Links TP, van Tol KM, Meerman GJ, de Vries EG. Differentiated thyroid carcinoma: a polygenic disease. Thyroid 2001; 11:1135–1140.CrossRefPubMed Links TP, van Tol KM, Meerman GJ, de Vries EG. Differentiated thyroid carcinoma: a polygenic disease. Thyroid 2001; 11:1135–1140.CrossRefPubMed
6.
go back to reference Lupoli G, Vitale G, Caraglia M, Fittipaldi MR, Abbruzzese A, Tagliaferri P, Bianco AR. Familial papillary thyroid microcarcinoma: a new clinical entity. Lancet 1999; 353:637–639.CrossRefPubMed Lupoli G, Vitale G, Caraglia M, Fittipaldi MR, Abbruzzese A, Tagliaferri P, Bianco AR. Familial papillary thyroid microcarcinoma: a new clinical entity. Lancet 1999; 353:637–639.CrossRefPubMed
7.
go back to reference Lloyd KM, Dennis M. Cowden’s disease: a possible new symptom complex with multiple system involvement. Ann Intern Med 1963; 58:136–142.PubMed Lloyd KM, Dennis M. Cowden’s disease: a possible new symptom complex with multiple system involvement. Ann Intern Med 1963; 58:136–142.PubMed
8.
go back to reference Lal G, Gallinger S. Familial adenomatous polyposis. Semin Surg Oncol 2000; 18:314–323.PubMed Lal G, Gallinger S. Familial adenomatous polyposis. Semin Surg Oncol 2000; 18:314–323.PubMed
9.
go back to reference Muir C, Waterhouse J, Mack T, Powell J. Cancer incidence in five continents, vol V. IARC Scientific Publications, no. 88. Lyon: International Agency for Cancer Research, 1987. Muir C, Waterhouse J, Mack T, Powell J. Cancer incidence in five continents, vol V. IARC Scientific Publications, no. 88. Lyon: International Agency for Cancer Research, 1987.
10.
go back to reference Parkin DM, Muir CS, Wheelan SL, Gao YT. Cancer incidence in five continents, vol VI. IARC Scientific Publications, no. 120. Lyon: International Agency for Cancer Research, 1992. Parkin DM, Muir CS, Wheelan SL, Gao YT. Cancer incidence in five continents, vol VI. IARC Scientific Publications, no. 120. Lyon: International Agency for Cancer Research, 1992.
11.
go back to reference Parkin DM, Wheelan SL, Ferlay J, Raymond L, Young J. Cancer incidence in five continents, vol VII. IARC Scientific Publications, no. 143. Lyon: International Agency for Cancer Research, 1997. Parkin DM, Wheelan SL, Ferlay J, Raymond L, Young J. Cancer incidence in five continents, vol VII. IARC Scientific Publications, no. 143. Lyon: International Agency for Cancer Research, 1997.
12.
go back to reference Parkin DM, Wheelan SL, Ferlay J, Teppo L, Thomas D. Cancer incidence in five continents, vol VIII. IARC Scientific Publications, no. 155. Lyon: International Agency for Cancer Research, 2002. Parkin DM, Wheelan SL, Ferlay J, Teppo L, Thomas D. Cancer incidence in five continents, vol VIII. IARC Scientific Publications, no. 155. Lyon: International Agency for Cancer Research, 2002.
13.
go back to reference Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457–481. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457–481.
14.
go back to reference Cox DR. Regression models and life tables (with discussion). J R Stat Soc B 1972; 34:187–220. Cox DR. Regression models and life tables (with discussion). J R Stat Soc B 1972; 34:187–220.
15.
go back to reference Annuaire statistique de la France. Institut National de la Statistique et des Etudes Economiques (INSEE), 105e edn. Paris, 2002. Annuaire statistique de la France. Institut National de la Statistique et des Etudes Economiques (INSEE), 105e edn. Paris, 2002.
16.
go back to reference Rothman KJ, Boice JD. Epidemiologic analysis with a programmable calculator. Boston: Epidemiology Resources Inc, 1982. Rothman KJ, Boice JD. Epidemiologic analysis with a programmable calculator. Boston: Epidemiology Resources Inc, 1982.
17.
go back to reference Stata Statistical Software. Release 7.0. College Station, TX: Stata Corporation, 2001. Stata Statistical Software. Release 7.0. College Station, TX: Stata Corporation, 2001.
18.
go back to reference Ng AK, Bernardo MV, Weller E, Backstrand K, Silver B, Marcus KC, Tarbell NJ, Stevenson MA, Friedberg JW, Mauch PM. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood 2002; 100:1989–1996.CrossRefPubMed Ng AK, Bernardo MV, Weller E, Backstrand K, Silver B, Marcus KC, Tarbell NJ, Stevenson MA, Friedberg JW, Mauch PM. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood 2002; 100:1989–1996.CrossRefPubMed
19.
go back to reference Rubino C, de Vathaire F, Dottorini ME, Hall P, Schvartz C, Couette JE, Dondon MG, Abbas MT, Langlois C, Schlumberger M. Second primary malignancies in thyroid cancer patients. Br J Cancer 2003; 89:1638–1644.CrossRefPubMed Rubino C, de Vathaire F, Dottorini ME, Hall P, Schvartz C, Couette JE, Dondon MG, Abbas MT, Langlois C, Schlumberger M. Second primary malignancies in thyroid cancer patients. Br J Cancer 2003; 89:1638–1644.CrossRefPubMed
20.
go back to reference Edmonds CJ, Smith T. The long-term hazards of the treatment of thyroid cancer with radioiodine. Br J Radiol 1986; 59:45–51.PubMed Edmonds CJ, Smith T. The long-term hazards of the treatment of thyroid cancer with radioiodine. Br J Radiol 1986; 59:45–51.PubMed
21.
go back to reference Akslen LA, Glattre E. Second malignancies in thyroid cancer patients: a population-based survey of 3658 cases from Norway. Eur J Cancer 1992; 28:491–495.PubMed Akslen LA, Glattre E. Second malignancies in thyroid cancer patients: a population-based survey of 3658 cases from Norway. Eur J Cancer 1992; 28:491–495.PubMed
22.
go back to reference Hall P, Holm LE, Lundell G. Second primary tumors following thyroid cancer. A Swedish record-linkage study. Acta Oncol 1990; 29:869–873.PubMed Hall P, Holm LE, Lundell G. Second primary tumors following thyroid cancer. A Swedish record-linkage study. Acta Oncol 1990; 29:869–873.PubMed
23.
go back to reference Pal T, Vogl FD, Chappuis PO, Tsang R, Brierley J, Renard H, Sanders K, Kantemiroff T, Bagha S, Goldgar DE, Narod SA, Foulkes WD. Increased risk for nonmedullary thyroid cancer in the first degree relatives of prevalent cases of nonmedullary thyroid cancer: a hospital-based study. J Clin Endocrinol Metab 2001; 86:5307–5312.PubMed Pal T, Vogl FD, Chappuis PO, Tsang R, Brierley J, Renard H, Sanders K, Kantemiroff T, Bagha S, Goldgar DE, Narod SA, Foulkes WD. Increased risk for nonmedullary thyroid cancer in the first degree relatives of prevalent cases of nonmedullary thyroid cancer: a hospital-based study. J Clin Endocrinol Metab 2001; 86:5307–5312.PubMed
24.
go back to reference Goldgar DE, Easton DF, Cannon-Albright LA, Skolnick MH. Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst 1994; 86:1600–1608.PubMed Goldgar DE, Easton DF, Cannon-Albright LA, Skolnick MH. Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst 1994; 86:1600–1608.PubMed
25.
go back to reference Wartofsky L, Sherman SI, Gopal J, Schlumberger M, Hay ID. The use of radioactive iodine in patients with papillary and follicular thyroid cancer. J Clin Endocrinol Metab 1998; 83:4195–4203.PubMed Wartofsky L, Sherman SI, Gopal J, Schlumberger M, Hay ID. The use of radioactive iodine in patients with papillary and follicular thyroid cancer. J Clin Endocrinol Metab 1998; 83:4195–4203.PubMed
26.
go back to reference Klain M, Ricard M, Leboulleux S, Baudin E, Schlumberger M. Radioiodine therapy for papillary and follicular thyroid carcinoma. Eur J Nucl Med Mol Imaging 2002; 29 Suppl 2:S479–S485. Klain M, Ricard M, Leboulleux S, Baudin E, Schlumberger M. Radioiodine therapy for papillary and follicular thyroid carcinoma. Eur J Nucl Med Mol Imaging 2002; 29 Suppl 2:S479–S485.
27.
go back to reference Mazzaferri EL, Kloos RT. Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001; 86:1447–1463. Mazzaferri EL, Kloos RT. Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001; 86:1447–1463.
Metadata
Title
Risk of second primary cancer following differentiated thyroid cancer
Authors
Emmanuelle Berthe
Michel Henry-Amar
Jean-Jacques Michels
Jean-Pierre Rame
Pascaline Berthet
Emmanuel Babin
Philippe Icard
Guy Samama
Françoise Galateau-Sallé
Jacques Mahoudeau
Stéphane Bardet
Publication date
01-05-2004
Publisher
Springer-Verlag
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 5/2004
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-003-1448-y

Other articles of this Issue 5/2004

European Journal of Nuclear Medicine and Molecular Imaging 5/2004 Go to the issue